Miransertib clinical trials
Also written ARQ 092 and MK-7075.
- studies test it
- 6
- open now
- 0
- in phase 3
- 0
- first study started
- 2011
How each study uses Miransertib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2015 (2)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2015 | 2 |
| 2017 | 1 |
| 2021 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 2
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) (3) · National Human Genome Research Institute (NHGRI) (2) · Merck Sharp & Dohme LLC (1)
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Studies
Open first, then newest update. How each study uses Miransertib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- MK-7075 (Miransertib) in Proteus SyndromeActive, not recruitingPhase 2National Human Genome Research Institute (NHGRI)NCT04316546Written as MK-7075 (miransertib)
- A Study of the Safety and Tolerability in Participants With PIK3CA-related Overgrowth Spectrum or Proteus Syndrome Who Are Being Treated With Miransertib (MK-7075) in Other Studies (MK-7075-006)Active, not recruitingPhase 2Merck Sharp & Dohme LLCNCT04980872Written as Miransertib
- Study of Miransertib (MK-7075) in Participants With PIK3CA-related Overgrowth Spectrum and Proteus Syndrome (MOSAIC) (MK-7075-002)TerminatedPhase 1/2ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)NCT03094832Written as Miransertib
- Dose Finding Trial of MK-7075 in Children and Adults With Proteus SyndromeCompletedPhase 1National Human Genome Research Institute (NHGRI)NCT02594215Written as MK-7075 (miransertib)
- Open-label Phase 1b Study of ARQ 092 in Combination With AnastrozoleTerminatedPhase 1ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)NCT02476955Written as ARQ 092 + carboplatin + paclitaxel (Closed)
- Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant LymphomaCompletedPhase 1ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)NCT01473095Written as ARQ 092
Codes
What other systems call Miransertib · ClinicalTrials.gg INT000485
- MeSH (NLM) C000608559MiransertibOne source NLM
- UNII (FDA) T1DQI1B52YMIRANSERTIBConfirmed FDA, NLM
- NCI Thesaurus C99172MiransertibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000608559 | Miransertib | One source NLM |
| UNII (FDA) | T1DQI1B52Y | MIRANSERTIB | Confirmed FDA, NLM |
| NCI Thesaurus | C99172 | Miransertib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.